Overall, the results demonstrate that CD8 T-cell responses to AFP are detectable in control groups (28.5%), as well as in Okuda tumour stage I HCC patients (25%) and Okuda tumour stage II+III HCC patients (31.6%). This evidence concerns the gene CD8A and hepatocellular carcinoma.